Cyclin-Dependent Kinase Inhibitor Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 50+ Leading Players Wheeling the Therapeutics Landscape

New York, USA, June 21, 2023 (GLOBE NEWSWIRE) — Cyclin-Dependent Kinase Inhibitor Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 50+ Leading Players Wheeling the Therapeutics Landscape

The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Cancer and the growing research and development activities to develop Cyclin-Dependent Kinase Inhibitor therapies in treating various Cancers drives the market. The companies developing the potential therapies in the last stage of development include Genor Pharma, Jiangsu Hengrui Medicine Co., Vincerx Pharma, and several others.

DelveInsight’s ‘Cyclin-Dependent Kinase Inhibitor Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline cyclin-dependent kinase inhibitors in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the cyclin-dependent kinase inhibitor pipeline domain.

Key Takeaways from the Cyclin-Dependent Kinase Inhibitor Pipeline Report

• DelveInsight’s cyclin-dependent kinase inhibitor pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline cyclin-dependent kinase inhibitors. 
• Key cyclin-dependent kinase inhibitors companies such as Syros Pharmaceuticals, Jiangsu Hengrui Medicine, Aucentra Therapeutics, MEI Pharma, Vincerx Pharma, Chordia Therapeutics, Pfizer, Novartis Pharmaceuticals, TYK Medicine, BioTheryX, Concarlo Therapeutics, Eli Lilly and Company, Kronos Bio, OnQuality Pharmaceuticals, Incyte Corporation, G1 Therapeutics, Blueprint Medicines, Cyclacel Pharmaceuticals, Nerviano Medical Sciences, Vichem Chemie, Prelude Therapeutics, Exelixis, -Qurient Co. Ltd., Kirilys Therapeutics, Sumitomo Pharma Oncology, Insilico Medicine, Cedilla Therapeutics, Relay Therapeutics, and others are evaluating new cyclin-dependent kinase inhibitor drugs to improve the treatment landscape.
• Promising cyclin-dependent kinase inhibitors in the pipeline such as SY-5609, SHR-6390, Auceliciclib, AU2-94, AU14-5, AU2-85, AU4-53, Voruciclib, VIP-152, CTX-439, Palbociclib, Ribociclib, TY-0540, BTX-9341, NP-ALT, Abemaciclib, KB-0742, OQL-051, INCB0123667, Lerociclib, BLU-222, Fadraciclib, Milciclib, Otviciclib, PRT2527, XL 102, Q 901,  KRLS 017, TP-1287, PRT3645, RLY-2139, and others are under different phases of cyclin-dependent kinase inhibitor clinical trials.
• In April 2023, Insilico Medicine announced that it has successfully discovered a potent, selective, and orally bioavailable small molecule inhibitor of CDK8 for the treatment of cancer using a structure-based generative chemistry approach enabled by the Chemistry42 multi-modal generative reinforcement learning platform. The research was published in the American Chemical Society’s Journal of Medicinal Chemistry, a leading journal in medicinal chemistry.
• In April 2023, Sumitomo Pharma Oncology, Inc., announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for TP-1287, an investigational oral CDK9 inhibitor, for the treatment of Ewing sarcoma. TP-1287 is an investigational oral phosphate prodrug of the CDK9 inhibitor alvocidib.
• In March 2023, Prelude Therapeutics Incorporated (Prelude)announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in combination with BeiGene’s BTK inhibitor, zanubrutinib, in hematologic malignancies. Under the terms of the clinical trial collaboration agreement, BeiGene will provide zanubrutinib to Prelude, and Prelude will retain all global operational, development, and commercialization rights and responsibilities for PRT2527.
• In September 2022, Syros Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SY-5609 for the treatment of pancreatic cancer. SY-5609, a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, is currently being evaluated in combination with chemotherapy for the treatment of patients with relapsed metastatic pancreatic cancer.
• In September 2022, Qurient Co. Ltd. announced that the company has entered into a clinical collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ., USA), for clinical study of Q901, a selective CDK7 inhibitor in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab). Under this agreement, Qurient will conduct a phase 1/2 study in the U.S. to evaluate the safety and efficacy of Q901 in combination with KEYTRUDA for the treatment of selected advanced solid tumors.
• In March 2022, Kirilys Therapeutics, Inc., announced that the Company completed a seed financing led by Lightspeed Venture Partners. The company licensed its lead compound, KRLS-017, from Ube Industries, Ltd., a premier Japanese chemical manufacturer. The company also completed a partnership agreement with D2G Oncology, Inc. which uses genetically defined animal tumor models to reveal relationships between cancer genotypes and drug efficacy. This financing round enabled Kirilys to complete all activities through the IND filing of KRLS-017, as well as preparatory work for the Phase 1 clinical development program.

Request a sample and discover the recent advances in cyclin-dependent kinase inhibitor drugs @ Cyclin-Dependent Kinase Inhibitor Pipeline Report

The cyclin-dependent kinase inhibitor pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage cyclin-dependent kinase inhibitor drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the cyclin-dependent kinase inhibitor clinical trial landscape.

Cyclin-Dependent Kinase Inhibitor Overview

Cyclin-dependent kinases (CDKs) are a class of enzymes known as serine-threonine kinases that play important roles in cell-cycle progression and transcription regulation under normal physiological settings. Some CDKs and their related cyclins and the downregulation of CDK inhibitors (CKIs) can cause aberrant cellular proliferation and cancer progression. Because CDKs are dysregulated in many malignancies, targeting this enzyme family has emerged as a viable technique in the treatment of a variety of cancer types, including blood and solid tumors. To date, the most successful method in the clinic has been targeting the cell cycle via the CDK4/6-Rb axis. The CDK4/6 inhibitors palbociclib, abemaciclib, and ribociclib have been approved by the FDA as therapies for hormone receptor-positive (HR+) metastatic breast cancer (mBC), in combination with endocrine therapy.

Find out more about cyclin-dependent kinase inhibitor @ Cyclin-Dependent Kinase Inhibitor Drugs

A snapshot of the Cyclin-Dependent Kinase Inhibitor Pipeline Drugs mentioned in the report:

Learn more about the emerging cyclin-dependent kinase inhibitor @ Cyclin-Dependent Kinase Inhibitor Clinical Trials

Cyclin-Dependent Kinase Inhibitor Therapeutics Assessment

The cyclin-dependent kinase inhibitor pipeline report proffers an integral view of the emerging cyclin-dependent kinase inhibitor segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Cyclin-Dependent Kinase Inhibitor Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
• Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
• Key Cyclin-Dependent Kinase Inhibitor Companies: Syros Pharmaceuticals, Jiangsu Hengrui Medicine, Aucentra Therapeutics, MEI Pharma, Vincerx Pharma, Chordia Therapeutics, Pfizer, Novartis Pharmaceuticals, TYK Medicine, BioTheryX, Concarlo Therapeutics, Eli Lilly and Company, Kronos Bio, OnQuality Pharmaceuticals, Incyte Corporation, G1 Therapeutics, Blueprint Medicines, Cyclacel Pharmaceuticals, Nerviano Medical Sciences, Vichem Chemie, Prelude Therapeutics, Exelixis, -Qurient Co. Ltd., Kirilys Therapeutics, Sumitomo Pharma Oncology, Insilico Medicine, Cedilla Therapeutics, Relay Therapeutics and others
• Key Cyclin-Dependent Kinase Inhibitor Pipeline Therapies: SY-5609, SHR-6390, Auceliciclib, AU2-94, AU14-5, AU2-85, AU4-53, Voruciclib, VIP-152, CTX-439, Palbociclib, Ribociclib, TY-0540, BTX-9341, NP-ALT, Abemaciclib, KB-0742, OQL-051, INCB0123667, Lerociclib, BLU-222, Fadraciclib, Milciclib, Otviciclib, PRT2527, XL 102, Q 901,  KRLS 017, TP-1287, PRT3645, RLY-2139 and others

Dive deep into rich insights for new cyclin-dependent kinase inhibitor, visit @ Pipeline Cyclin-Dependent Kinase Inhibitor Drugs

Table of Contents

For further information on the cyclin-dependent kinase inhibitor pipeline therapeutics, reach out @ Cyclin-Dependent Kinase Inhibitor Analysis

Related Reports

Immune Checkpoint Inhibitors Competitive Landscape

Immune Checkpoint Inhibitors Competitive Landscape and Market Forecast – 2032 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key immune checkpoint inhibitors companies, including Regeneron, Bristol-Myers-Squibb, Novartis, GlaxoSmithKline, Merck, Roche, and AstraZeneca, among others.

Checkpoint Inhibitors Competitive Landscape

Checkpoint Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key checkpoint inhibitors companies, including BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, Eucure Biopharma, PharmaEngine, Vernalis, Array BioPharma, Genentech, Boehringer Ingelheim, Sentinel Oncology, Sierra Oncology, IMPACT Therapeutics, among others.

PD-1 Inhibitor Pipeline

PD-1 Inhibitor Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 inhibitor companies, including Genmab, RemeGen, Alphamab, OxSonics therapeutics, Light Chain Bioscience, ImmuneOnco Biopharma, Alpine Immune Sciences, Shanghai Henlius Biotech, Inc., Ocean Biomedical, Akeso Biopharma, Lyvgen Biopharma, Prestige Biopharma, ONO PHARMACEUTICAL CO., LTD., among others.

PD-1 and PD-L1 Inhibitors Competitive Landscape

PD-1 and PD-L1 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen Inc., Ascletis Pharma Inc., Secarna Pharmaceuticals GmbH & Co. KG, Arbutus Biopharma, among others.

JAK Inhibitors Competitive Landscape

JAK Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others.

TIGIT Inhibitors Competitive Landscape

TIGIT Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TIGIT inhibitors companies, including Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, among others.

Other Trending Reports

Alopecia Market | Invasive Candidiasis Market | Bronchial Spasm Market | Chronic Gout Market | Hpv-Induced Cancers Market | Meningioma Market | Lewy Body Dementia Market | Anti-Gbm Disease Market | Colorectal Cancer CRC Market | Cervical Intraepithelial Neoplasia Market | Carpal Tunnel Syndrome Market | Nonalcoholic Steatohepatitis Market | AIDS Related Kaposis Sarcoma Market | Progressive Supranuclear Palsy Market | Tropical Spastic Paraparesis Market | Secondary Progressive Multiple Sclerosis SPMS Market | Systemic Sclerosis-Associated Interstitial Lung Disease Market | Reactive Airway Disease Market | Ptosis Market | AL Amyloidosis Market | Abdominal Aortic Aneurysm Market | X-Linked Retinitis Pigmentosa Market

Related Healthcare Blogs

Upcoming Oncological Drugs in 2023

Metastatic Castration-Sensitive Prostate Cancer Treatment Market

Checkpoint Inhibitor Refractory Cancer Market

Promising Oncolytic Virues Candidates in Pipeline

Cancer Biomarkers: Improving Treatment and Detection

Minimal Residual Disease (MRD) Testing: A Path to Cure Cancer?

ENHERTU’s Journey in Cancer Treatment and Management

Potential of PD-1 and PD-L1 Inhibitors in Cancer Management

Evolving EGFR NSCLC Treatment Market Dynamics

Emerging Role of Digital Health in the Field of Oncology

Related Cases Studies

Competitive Intelligence

Market Assessment

Product Assessment

Epidemiology Assessment

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn